A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Neo-adjuvant chemotherapy
Sponsor: Hoffmann-La Roche